Novel therapies for chronic lymphocytic leukemia (Q34304235)

1 August 2017

1 reference

title

Novel therapies for chronic lymphocytic leukemia (English)

1 reference

1 August 2017

0 references

1 reference

2

Bruce D Cheson

1 reference

1 August 2017

Blanche H Mavromatis

1

1 reference

1 August 2017

publication date

1 June 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

18

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

137-148

1 reference

1 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Update on the biology of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Radioimmunotherapy of non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1016/S0268-960X(03)50039-0

7 January 2021

10.1016/S0268-960X(03)00039-0

Identifiers

DOI

1 reference

1 August 2017

1 reference